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Abstract
Background: Pregnancy in patients with lipoprotein lipase deficiency is associated with high risk
of maternal pancreatitis and fetal death. A very low fat diet (< 10% of calories) is the primary
treatment modality for the prevention of acute pancreatitis, a rare but potentially serious
complication of severe hypertriglyceridemia. Since pregnancy can exacerbate hypertriglyceridemia
in the genetic absence of lipoprotein lipase, a further reduction of dietary fat intake to < 1–2% of
total caloric intake may be required during the pregnancy, along with the administration of a fibrate.
It is uncertain if essential fatty acid deficiency will develop in the mother and fetus with this
extremely low fat diet, or whether fibrates will cross the placenta and concentrate in the fetus.
Case presentation: A 23 year-old gravida 1 woman with primary lipoprotein lipase deficiency
was seen at 7 weeks of gestation in the Lipid Clinic for management of severe hypertriglyceridemia
that had worsened with pregnancy. While on her habitual fat intake of 10% of total calories, her
pregnancy resulted in an exacerbation of the hypertriglyceridemia, which prompted further
restriction of fat intake to < 2% of total calories, as well as administration of gemfibrozil at a lower
than average dose. The level of gemfibrozil, as the active metabolite, in the venous and arterial fetal
cord blood was within the expected therapeutic range for adults. The clinical signs and a biomarker
of essential fatty acid deficiency, namely the ratio of 20:3 [n-9] to 20:4 [n-6] fatty acids, were closely
monitored throughout her pregnancy. Despite her extremely low fat diet, the levels of essential
fatty acids measured in the mother and in the fetal blood immediately postpartum were normal.
Normal essential fatty acid levels may have been achieved by the topical application of sunflower oil.
Conclusions: An extremely low fat diet in combination with topical sunflower oil and gemfibrozil
administration was safely implemented in pregnancy associated with the severe
hypertriglyceridemia of lipoprotein lipase deficiency.
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Background
Primary lipoprotein lipase (LPL) deficiency is a rare auto-
somal recessive disorder characterized by severe hypertrig-
lyceridemia, due to the accumulation in plasma of
chylomicrons and very low density lipoproteins (VLDL)
that result from the absence of LPL activity [1]. The esti-
mated frequency of this disorder is <1 per million with the
carrier frequency at about 1 in 500. Clinically significant
hypertriglyceridemia usually manifests early in childhood
with dietary fat intolerance, including recurrent episodes
of abdominal pain and acute pancreatitis, failure to thrive,
eruptive xanthoma and hepatosplenomegaly. Very severe
hypertriglyceridemia during pregnancy can occur and is
associated with significant maternal morbidity and fetal
mortality [2-6]. Overproduction of hepatic VLDL in the
presence of decreased LPL activity contributes to the
marked increase in plasma triglyceride (TG) levels during
pregnancy [7,8].
The management of severe hypertriglyceridemia in a preg-
nant patient with LPL deficiency is directed toward pre-
venting pancreatitis in the mother and delivery of a
healthy infant. Lowering of plasma TG in the prevention
of pancreatitis is managed primarily by dietary fat restric-
tion, but additional TG lowering may be required and has
been reported with use of fibrates, such as gemfibrozil
[6,9,10]. Two major questions arose during the treatment
aimed at lowering the severe hypertriglyceridemia in this
pregnant LPL-deficient patient. First, would essential fatty
acid (EFA) deficiency develop in the mother and fetus as
a result of severe maternal dietary fat restriction? Second,
would gemfibrozil cross the placenta and concentrate in
the fetus? The strategies utilized to prevent EFA deficiency
and the fetal nutritional information obtained from stud-
ies at birth will address these questions and concerns.
Case presentation
Clinical history
The proband presented to her pediatrician at age 3 month
with failure to thrive. She was evaluated at the Children's
Hospital Medical Center in Seattle, where an elevated TG
level of 14,000 mg/dl (158 mmol/L) suggested hyperchy-
lomicronemia with LPL deficiency. Plasma post-heparin
LPL activity was absent, consistent with defective catabo-
lism of TG rich particles. Further study at the University of
Washington of her post-heparin plasma at age 19 revealed
absent LPL activity due to a defective LPL protein, while
her hepatic lipase activity was normal [11]. She was a
compound heterozygote with two missense mutations in
the LPL gene (Trp86-Arg/His136-Arg) [12]. On a self-
selected low fat diet (< 20% of dietary calories) she was
able to maintain her TG < 1000 mg/dl (11.3 mmol/L)
throughout a healthy and normal childhood and adult-
hood. Because of her excellent compliance with low die-
tary fat intake and active physical lifestyle, she had never
developed clinical pancreatitis. Throughout the years,
there were few episodes of mid epigastric abdominal dis-
comfort that subsided with short periods of fasting. She
had developed eruptive xanthoma briefly when oral con-
traceptives were used.
Pregnancy course
At the age of 23, the proband presented at week 7 of ges-
tation for management of anticipated worsening of hyper-
triglyceridemia in pregnancy. She had been in excellent
physical condition and had continued her routine 10–
20% fat diet during the first trimester (Figure 1). Her TG
was 396 mg/dl (4.5 mmol/L) at week 7 of gestation. When
she retuned to the University of Washington Medical
Center (UWMC) 5 weeks later, her TG levels had started
to rise and despite further restriction of dietary fat to <
10% of calories, the level had risen to 3705 mg/dl (41.9
mmol/L) by week 16. At week 28, she developed her first
episode of mid epigastric abdominal pain without ele-
vated serum amylase or pancreatic lipase levels, consistent
with subclinical pancreatitis. Remission of the symptoms
occurred within 2–3 days of a near zero dietary fat intake
as an outpatient. Subsequent reduction to less than 2% of
dietary fat was implemented with a liquid formula by the
following week, to decrease the risk of recurrent abdomi-
nal pain in the setting of extremely elevated TG levels
(3000–6000 mg/dl [33.9–67.8 mmol/L]). Gemfibrozil at
a low dose of 300 milligram (mg) twice a day was also ini-
tiated at week 29 to prevent a further upward trend in TG
in the third trimester. The dosage was increased to 300 mg
three times a day a week later. This appeared to stabilize
her TG in the 5000–6000 mg/dl (56.5 – 67.8 mmol/L)
range until week 34 when she developed severe abdomi-
nal pain. Initial evaluation at her local hospital revealed a
TG level of 6,050 mg/dl (68.4 mmol/L) and elevated pan-
creatic lipase (680 IU/dl) and amylase (1336 IU/L). She
was transferred and admitted to the UWMC and placed on
intravenous fluids. Two days later, her pancreatitis sub-
sided and she was placed back on the <2% fat diet and
900 mg/day of gemfibrozil. A second episode of pancrea-
titis a few days later prompted re-admission to UWMC for
labor induction at the 35th week of gestation. A 5 lb 3 oz
baby girl with a 5-minute Apgar score of 9 was delivered
vaginally. A short time after the delivery, the baby was
briefly intubated for about 48 hours due to respiratory
distress but did well subsequently. The patient's plasma
TG rapidly decreased to 2015 mg/dl (22.8 mmol/L)
within the first postpartum 24 hours, accompanied by
improved abdominal symptoms. Resumption of low fat
solid food brought back the symptoms of pancreatitis and
she was placed back on the IV fluids followed by a more
gradual incremental introduction of oral intake. Along
with 1,200 mg/day of gemfibrozil, she had complete res-
olution of abdominal symptoms by postpartum day-8
and eventual resolution two weeks after discharge of peri-BMC Pregnancy and Childbirth 2004, 4:27 http://www.biomedcentral.com/1471-2393/4/27
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pancreatic fluid accumulation demonstrated by CT imag-
ing studies. Now, 11 years later, the proband and her
daughter are both healthy and doing well. The proband's
TG levels are back to baseline and stable on 10–20% fat
diet. Her daughter has had normal TG and cholesterol lev-
els on regular diet.
Eruptive xanthomas, which are associated with hypertrig-
lyceridemia, developed on the proband's buttocks at week
20 and subsequently spread to the upper arms and medial
aspects of thighs as her TG levels rose. Peculiarly, palmar
xanthoma, typical of remnant removal disease (type III
hyperlipidemia), also developed at week 27. A concomi-
tant ex vivo investigation of the mechanisms contributing
to palmar xanthoma in the proband, who has an apo E 4/
E3 phenotype, revealed an enhanced macrophages uptake
of the TG rich lipoproteins as a result of an unusual
enrichment of these lipoproteins with apo E during preg-
nancy [13].
Gestational EFA profiles
Because of concern for unfavorable fetal neurological
development due to EFA deficiency, EFA profile was mon-
itored in the mother at each visit starting at gestational
week 23. The initial analyses were performed at the Clini-
cal Nutrition Research Unit (CNRU), Harborview Medical
Center campus of the University of Washington. After sep-
aration from cells, the fatty acids from the phospholipid
fraction of the plasma were extracted and subsequently
measured by capillary gas chromatography. In addition to
Serum triglyceride level and corresponding dietary fat intake and gemfibrozil administration during pregnancy Figure 1
Serum triglyceride level and corresponding dietary fat intake and gemfibrozil administration during pregnancy *Dietary fat was 
expressed as % of total caloric intake.
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the total amount and % of each FA, the ratio of eicosa-
trienoic acid (ETA, 20:3(n-9)) to arachidonic acid (AA,
20:4(n-6)) was calculated (Figure 2). This ratio was used
as an index to the patient's EFA status. By week 26, the
ratio had risen from 0.032 to 0.052 (Fig 2), suggesting a
trend to a less EFA abundant state [14]. Topical applica-
tion of sunflower oil containing large amounts of polyun-
saturated fatty acids (PUFA) was initiated as a non-oral
route for supplementing EFA because of its reported suc-
cess in EFA deficient subjects [15]. With 460 mg per day of
sunflower seed oil (approximately 240 mg of linoleic
acid) applied to her arms and trunk, her EFA profile
appeared to improve with the ratio stabilizing at 0.08 at
31 weeks. A peak to a ratio of 0.09 occurred at week 34
possibly due to irregular uses of topical PUFA (Figure 2).
Immediately postpartum, placental fetal blood and
maternal plasma was obtained for total fatty acid analysis
(Figure 3). These FA were measured by capillary gas/liquid
chromatography at the Oregon Health Sciences University
and expressed as % of total FA. In spite of low levels of n-
6 and n-3 fatty acids in maternal blood and similarly
decreased levels of PUFA precursors (linoleic [LA] and α-
linolenic acid [ALA]) in cord blood samples compared to
the reported normal reference range [16], there were
abundant long chain PUFA (such as arachidonic acid
[AA]) in the fetal circulation. This suggested that either the
topical application of sunflower seed oil during the late
stage of pregnancy prevented EFA deficiency or that the
fetus had increased capacity for obtaining EFA from the
mother.
Essential fatty acid profile in maternal blood Figure 2
Essential fatty acid profile in maternal blood EFA: essential fatty acids, from sunflower seed oil. Measurement was made in the 
phospholipid fractions. 20:3(n-9): eicosatrienoic acid (ETA). 20:4(n-6): arachidonic acid (AA).
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Gemfibrozil in fetal circulation
To examine whether there might be excessive accumula-
tion of gemfibrozil in the newborn baby, fetal cord blood
was obtained at the time of delivery and gemfibrozil levels
and its active compound, metabolite III, were measured.
The analysis was performed as a courtesy of the Research
Lab at the Parke-Davis Pharmaceutical (Ann Arbor, Mich-
igan) by high performance liquid chromatography
(HPLC) and revealed similar concentrations of the drug
and its active metabolites in both umbilical vein and
artery, which were within the normal reference range for
adults (Figure 4).
Conclusions
Children with primary LPL deficiency can be effectively
managed on fat-restricted diets and grow normally into
adulthood. However, they can present with extreme eleva-
tion of TG levels with serious acute pancreatitis. This LPL-
deficient subject developed severe hypertriglyceridemia in
early pregnancy, with eruptive xanthomas and pancreati-
tis. With the diligent efforts from the patient, her family,
and a team of specialists in lipid metabolism, dietetics,
high-risk obstetrics and gastroenterology, a successful out-
come was achieved. Outcome goals were clearly set at the
onset of her pregnancy care, including nutritional man-
agement of the expected rise in triglyceride levels
associated with the estrogen surge of pregnancy to prevent
Fatty acid composition in maternal and cord plasma Figure 3
Fatty acid composition in maternal and cord plasma LA: linoleic acid. ALA: α-linolenic acid. ETA: eicosatrienoic acid. AA: ara-
chidonic acid.
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acute pancreatitis, and avoidance of clinical EFA defi-
ciency in both the mother and the fetus.
Pregnancy and hypertriglyceridemia
Pregnancy-induced hypertriglyceridemia is estimated to
be the cause in 4–6% of all pancreatitis cases during preg-
nancy, while most cases result from cholelithiasis [4].
Hypertriglyceridemia-related pancreatitis in pregnancy
also has been reported due to other causes of severe hyper-
triglyceridemia [17]. Successful management requires
early detection of signs and symptoms of acute pancreati-
tis often accompanied by increases in serum lipase and
amylase levels and characteristic findings in imaging stud-
ies. Once the pancreatitis is suspected, these individuals
should be admitted for aggressive medical management
including intravenous hydration concurrent with no oral
intake of solids or liquids. Obstructive processes in the
biliary system need to be ruled out specifically since treat-
ment modalities are quite different.
Pregnancy and LPL deficiency
Pregnancy is a well known situation in which the physio-
logic estrogen surge profoundly alters the TG-rich lipopro-
tein metabolism, resulting in a gradual rise in TG levels
over the course of non-complicated pregnancy, peaking at
the level of 200–300 mg/dl (2.26 – 3.39 mmol/L) at term
[17]. During the first two trimesters of pregnancy, adipose
fat storage, as maternal fuels, occurs in preparation for an
active transfer of maternal glucose, amino acids, and free
fatty acids (FFA) across the placenta for accelerate fetal
growth in late phase of gestation [18]. In late gestation,
adipose tissue lipolysis is greatly augmented generating
Gemfibrozil metabolite III levels in the fetal cord blood Figure 4
Gemfibrozil metabolite III levels in the fetal cord blood *Ref. range: 0.5 – 40 µg/ml
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FFA and glycerol, for further hepatic VLDL production,
contributing to the flux of circulating TG-fatty acids in
pregnancy [18,19]. Greater concentration of chylomi-
crons from dietary fat as a result of maternal hyperphagia
in late pregnancy also contributes to the circulating TG-
rich lipoprotein pool [18,19], and provides alimentary
substrates for VLDL production [20,21]. LPL activities in
the liver, heart, and particularly adipose tissue are, how-
ever, reduced by an estimated total of 85% [19,22] in late
gestation. Concomitantly, clearance of circulating TG-rich
lipoproteins is reduced in late pregnancy. Hepatic lipase
activity is decreased as well and could explain the observa-
tion of parallel TG-enrichment of LDL and high-density
lipoproteins (HDL) particles during normal gestation. All
these changes take place to ensure a stable supply of fuel
substrates across the placenta for normal fetal develop-
ment while preserving maternal metabolic homeostasis
[18,19].
Very low fat diet and EFA deficiency
Arachidonic acid [AA, 20:4(n-6)], an important precursor
of the prostaglandin compounds, cannot be synthesized
de novo from FFA in mammals and must be derived from
another EFA in the diet, namely linoleic acid [LA, 18:2(n-
6)]. In the case of life long low oral fat intake, as in our
patient, clinical EFA deficiency might occur with deple-
tion of n-3 and n-6 FA stored in adipose tissue. Therefore,
her source of EFA would be entirely from recent dietary
intake and deficiency might occur sooner than in individ-
uals with normal LPL and abundant EFA storage [23].
Eicosatrienoic acid [ETA, 20:3(n-9)], on the other hand, is
not an EFA because it can be synthesized in mammals
from palmitic acid [16:1(n-9)]. In the event of diminish-
ing pool of both n-3 and n-6 fatty acids due to absence or
deficiency in the diet, more ETA are produced and the
amount parallels the degree of deficiency [24-26]. EFA
deficiency syndrome commonly results from a combined
deficiency in both n-3 and n-6 fatty acids. A ratio of ETA
to AA > 0.2, is suggestive of EFA deficiency [24-26].
Clinical manifestations in EFA deficiency are unusual on
a diet containing > 2% of the calories as linoleic acid [27].
While the clinical symptoms of dryness and desquama-
tion of the skin are annoying at best, a more serious con-
sequence could be impaired fetal brain and visual
development. The proband did not develop signs of clin-
ical EFA deficiency, nor did the ratio of 20:3(n-9) to
20:4(n-6) exceed 0.2 at any stage of her pregnancy,
although an upward trend did occur. Additionally, the
report that infants fed a formula low in EFA grew poorly
and developed multiple medical complications was a con-
cern [28]. Several reports have documented a reversal of
biochemical and clinical manifestations of EFA deficiency
in infants and adults by cutaneous administration of EFA-
rich oil, such as sunflower oil [29-35]. Therefore, applica-
tion of sunflower oil to the proband's skin was initiated at
week 25 and may have had prevented progression of EFA
deficiency in mother, as suggested by the stabilization of
the 20:3(n-9) to 20:4(n-6) ratio. Surprisingly, we found
low levels of n-3, n-6, and PUFA precursor levels in the
cord blood taken during the delivery, and yet there was
abundant long chain PUFA in the infant circulation. This
would suggest that other adaptive mechanisms were
involved in maintaining the critical levels of long chain
EFA in fetal circulation in the face of inadequate maternal
supply.
Use of gemfibrozil in LPL deficiency
Use of TG lowering drugs, such as gemfibrozil (a fibrate),
can be used to directly lower the triglyceride level in the
prevention of acute pancreatitis. Pregnancy induces
hepatic production of TG-rich VLDL and may respond to
fibrates through inhibition of hepatic production of
VLDL. Gemfibrozil, which is an FDA category C drug, has
not been observed to be associated with adverse drug
effects in reports of pregnancy-related severe hypertriglyc-
eridemia [6,10,36,37]. During the last few weeks of her
gestation low dose gemfibrozil in our subject seemed to
have stabilized her TG level (Fig 1), which might
otherwise have continued to rise due to the estrogen effect
on hepatic VLDL production in the third trimester. A
lower than usual dose of gemfibrozil was used due to the
concern for excess placental transfer of its metabolites that
has been reported in pregnant cats [38]. Analysis of the
parent compound and metabolites did not detect exces-
sive accumulation in the fetal cord circulation in contrast
to the reports in animal models. While this observation
needs to be independently confirmed, adverse drug effects
in the infants born to mothers on gemfibrozil or other
fibrates have not been reported. Moreover, gemfibrozil
has been used and appears to be free of short-term side
effects in pediatric populations [39-42]. Therefore, low
dose gemfibrozil may be safe for use during the last tri-
mester in hyperlipidemic patients at high risks for acute
pancreatitis.
In conclusion, a successful pregnancy outcome was
achieved in our LPL deficient patient, confirming previous
reports [6,43] that aggressive lipid lowering strategies
under the supervision of experienced health care provid-
ers works in this high risk setting. Although the patient
developed pancreatitis during her pregnancy, the use of an
extremely low fat diet together with a fibrate helped limit
the increase in the triglycerides, and her pancreatitis was
neither life threatening nor adversely affected fetal sur-
vival. Sunflower oil applied topically may have helped
prevent EFA deficiency in both the mother and fetus. Use
of gemfibrozil did not appear to have any adverse effect
on the child. Thus, the use of these two therapeutic
approaches appears safe and appropriate in the medical
management of pregnancy-associated severe hypertriglyc-BMC Pregnancy and Childbirth 2004, 4:27 http://www.biomedcentral.com/1471-2393/4/27
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eridemia, where EFA deficiency and recurrent pancreatitis
are major concerns.
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